Lincoln Pharmaceuticals (531633) Q4 07/08 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 07/08 earnings summary
14 Oct, 2026Executive summary
FY08 sales rose 36% to ₹8,623.18 lakh; profit after tax increased to ₹466.26 lakh from ₹304.76 lakh.
Performance was supported by growth in pharmaceutical sales and new chemical trading revenue; a 12% dividend was recommended, unchanged YoY.
Financial highlights
Sales ₹8,623.18 lakh vs ₹6,339.39 lakh in FY07; total income ₹8,497.40 lakh vs ₹6,546.01 lakh, reflecting negative stock variation in FY08.
PBT ₹652.02 lakh vs ₹440.22 lakh; PAT ₹466.26 lakh vs ₹304.76 lakh.
Profit before depreciation and tax ₹722.69 lakh vs ₹496.01 lakh.
Outlook and guidance
FY09 outlook was cautiously optimistic, targeting greater share through new products, wider geographic reach and larger job contracts.
Plans included job work for multinational companies, expanding the product range and building brand image.
Latest events from Lincoln Pharmaceuticals
- Sales grew 23%, while Khatraj delays constrained results and the expansion outlook.531633
Q4 96/97 - Profit improved YoY, but delayed expansion and recession kept results well below plan.531633Q4 97/98
- Sales and profit grew, but operating cash flow swung negative.531633Q4 98/99
- FY2000 sales and net profit rose; exports fell and no dividend was proposed.531633Q4 99/00
- Sales rose to Rs 3,356.16 lacs and net profit to Rs 144.24 lacs in FY03.531633Q4 02/03
- Sales and net profit advanced as expansion plans faced competition and rising costs.531633Q4 03/04
- Sales grew, but profit fell; a 12% dividend and cautious growth plans followed.531633Q4 04/05
- Sales rose 49% as PAT grew, with new products and job work targeted for further growth.531633Q4 05/06
- Sales rose 12.25% as PAT increased to Rs 304.76 lakh amid competitive pressure.531633Q4 06/07